Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ocean Biomedical, Inc. amended Definitive A&R Backstop Agreement with Vellar Opportunity Fund SPV LLC – Series 3 valued at increase the maximum number of shares Vellar may purchase under the Definitive A&R Backstop Agreemen (effective 2023-02-12).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- Vellar Opportunity Fund SPV LLC – Series 3
- Value
- increase the maximum number of shares Vellar may purchase under the Definitive A&R Backstop Agreemen
- Effective
- 2023-02-12
Exact text from the filing
On February 12, 2023, Aesther, Ocean Biomedical and Vellar again amended and restated the Original Backstop Agreement (the “ Definitive A&R Backstop Agreement ”), a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference, to increase the maximum number of shares Vellar may purchase under the Definitive A&R Backstop Agreement from 6,000,000 to 8,000,000.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ocean Biomedical, Inc. entered into Agreement and Plan of Merger with Aesther Healthcare Acquisition Corp., AHAC Merger Sub, Inc., Aesther Healthcare Sponsor, LLC, Ocean Biomedical, Inc., and Dr. Chirinjeev Kathuria (effective 2022-08-31).
- Action
- entry
- Agreement
- merger
- Counterparty
- Aesther Healthcare Acquisition Corp., AHAC Merger Sub, Inc., Aesther Healthcare Sponsor, LLC, Ocean Biomedical, Inc., and Dr. Chirinjeev Kathuria
- Effective
- 2022-08-31
Exact text from the filing
On August 31, 2022, Aesther Healthcare Acquisition Corp., a Delaware corporation (“ Aesther ”) entered into an Agreement and Plan of Merger by and among Aesther, AHAC Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Aesther (“ Merger Sub ”), Aesther Healthcare Sponsor, LLC, Aesther’s sponsor (the “ Sponsor ”), in its capacity as purchaser representative, Ocean Biomedical, Inc., a Delaware corporation (“ Ocean Biomedical ”), and Dr. Chirinjeev Kathuria, in his capacity as seller representative (as may be amended and/or restated from time to time, the “ Merger Agreement ”)
View on SEC.gov